Saladax, CESAR Partner on Study of 5-FU Dosing for Colorectal Cancer | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Saladax Biomedical announced today a collaborative study of metastatic colorectal cancer patients treated with 5-fluorouracil, or 5-FU, and whose doses will be optimized based on actual 5-FU blood levels.

As part of the collaboration with the Central European Society for Anticancer Drug Research, or CESAR, Saladax's My5-FU immunoassay technology will be used to measure 5-FU levels.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.